Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism

CNS Drugs
Andrea de BartolomeisFelice Iasevoli

Abstract

Dopamine partial agonism and functional selectivity have been innovative strategies in the pharmacological treatment of schizophrenia and mood disorders and have shifted the concept of dopamine modulation beyond the established approach of dopamine D2 receptor (D2R) antagonism. Despite the fact that aripiprazole was introduced in therapy more than 12 years ago, many questions are still unresolved regarding the complexity of the effects of this agent on signal transduction and intracellular pathways, in part linked to its pleiotropic receptor profile. The complexity of the mechanism of action has progressively shifted the conceptualization of this agent from partial agonism to functional selectivity. From the induction of early genes to modulation of scaffolding proteins and activation of transcription factors, aripiprazole has been shown to affect multiple cellular pathways and several cortical and subcortical neurotransmitter circuitries. Growing evidence shows that, beyond the consequences of D2R occupancy, aripiprazole has a unique neurobiology among available antipsychotics. The effect of chronic administration of aripiprazole on D2R affinity state and number has been especially highlighted, with relevant translational impl...Continue Reading

References

Nov 1, 1978·The American Journal of Psychiatry·G ChouinardL Annable
Jan 1, 1992·Schizophrenia Bulletin·R RamJ E Schwartz
Jan 1, 1991·Journal of Neural Transmission. General Section·R Olbrich, H Schanz
Oct 1, 1994·Trends in Pharmacological Sciences·L Pulvirenti, G F Koob
Jan 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·O BenkertH Wetzel
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·A BreierD Pickar
Jan 14, 1998·Trends in Pharmacological Sciences·T Kenakin
Mar 26, 1998·Journal of Medicinal Chemistry·D WustrowL Wise
May 18, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C P LawlerR B Mailman
Oct 4, 2000·British Journal of Pharmacology·J ZhuI Muramatsu
Jun 1, 2001·The American Journal of Psychiatry·R A BressanL S Pilowsky
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C OrsiniL Pulvirenti
Apr 17, 2002·Journal of Neural Transmission·C A Tamminga
May 23, 2002·The Journal of Pharmacology and Experimental Therapeutics·David M MottolaRichard B Mailman
May 23, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jason D KiltsRichard B Mailman
Jun 14, 2002·European Journal of Pharmacology·Shaun JordanC Anthony Altar
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff
Jul 3, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Fuji YokoiDean F Wong
Sep 14, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ina KochLeszek Wojnowski
Oct 31, 2002·Advanced Drug Delivery Reviews·Jatinder K LambaKenneth E Thummel
Dec 24, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Rebecca J Ralph-WilliamsMark A Geyer
May 29, 2003·Current Drug Targets. CNS and Neurological Disorders·C A Tamminga, A Carlsson
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David A ShapiroRichard Mailman
Jul 3, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Peter TurroneJosé N Nobrega
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shitij Kapur, David Mamo
Jan 8, 2004·European Journal of Pharmacology·Shaun JordanC Anthony Altar
Feb 12, 2005·Biological Psychiatry·Peter TurroneJosé N Nobrega

❮ Previous
Next ❯

Citations

Mar 11, 2016·Cortex; a Journal Devoted to the Study of the Nervous System and Behavior·Cécile DelormeYulia Worbe
Apr 22, 2016·Expert Opinion on Investigational Drugs·Giovanni MartinottiMassimo Di Giannantonio
Jun 9, 2016·Korean journal of family medicine·Ather Muneer
Jun 28, 2016·Expert Opinion on Drug Safety·L OrsoliniD De Berardis
Jul 28, 2016·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Mahmoud SlimRaul J Andrade
Sep 21, 2016·Brain : a Journal of Neurology·Maria do Carmo CostaHenry L Paulson
Nov 8, 2016·Case Reports in Psychiatry·Edwige HeitzmannBruno Michel
Oct 30, 2016·Biochemical and Biophysical Research Communications·Minoru AsadaHidenori Suzuki
Dec 23, 2016·Brain : a Journal of Neurology·Ahmad Seif KanaanKirsten Müller-Vahl
Mar 24, 2017·Chemical Research in Toxicology·John E Casida
Mar 17, 2017·Journal of Medicinal Chemistry·Alessandro BonifaziAmy Hauck Newman
Apr 30, 2017·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Ather Muneer
Dec 3, 2016·Neurochemical Research·Marta Jóźwiak-Bębenista, Edward Kowalczyk
Jun 26, 2017·Psychotherapy and Psychosomatics·Guy ChouinardMasaomi Iyo
Feb 15, 2018·Pharmacotherapy·Heather Torbic, Abhijit Duggal
Aug 8, 2018·The International Journal of Neuropsychopharmacology·Kelly A Berg, William P Clarke
Aug 25, 2018·Expert Opinion on Drug Metabolism & Toxicology·Kaat HebbrechtBernard G C Sabbe
Mar 17, 2018·BMJ Case Reports·Simon S RabinowitzJennifer Gottfried
Feb 4, 2016·Nature Nanotechnology·Christian Martin
May 11, 2019·Expert Opinion on Drug Safety·Alessandro CuomoAndrea Fagiolini
Jun 11, 2019·Expert Opinion on Pharmacotherapy·Lindsay A BartramDaniel L Coury
Jul 2, 2019·Physical Chemistry Chemical Physics : PCCP·Jose E M PereiraHeloisa N Bordallo
Nov 2, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Lígia CastanheiraRicardo Coentre
Jan 15, 2020·International Journal of Psychiatry in Clinical Practice·Juan Carlos García ÁlvarezEnrique Pérez Martínez
May 15, 2018·Frontiers in Behavioral Neuroscience·Francisco T GalloNoelia V Weisstaub
Aug 9, 2020·Frontiers in Neuroscience·Georg A Petroianu, Dietrich E Lorke
Mar 25, 2019·Psychopharmacology·Thomas LapointeFrancesco Leri
May 1, 2020·Frontiers in Psychiatry·Andrea MiuliMassimo di Giannantonio
May 24, 2020·Acta neurologica Belgica·Upinder KaurSankha Shubhra Chakrabarti
Sep 29, 2020·Internal Medicine Journal·Michael M C WongK Y Mak
Mar 24, 2017·The International Journal of Eating Disorders·Guido K W FrankBrogan Rossi
Feb 12, 2019·Journal of Psychoactive Drugs·Lorenzo MocciaMarco Di Nicola
Aug 14, 2019·The International Journal of Neuropsychopharmacology·Jasmina MalletCaroline Dubertret
Nov 5, 2019·Frontiers in Psychiatry·Dimy FluyauKervens Lorthe

❮ Previous
Next ❯

Methods Mentioned

BETA
GTPase
ISSH

Clinical Trials Mentioned

NCT00658645

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here